OncoXome is a preclinical-stage biotech developing a tumor-targeted exosome delivery platform for CRISPR-based therapies. Our lead program targets KRAS-mutant colorectal cancer, with expansion potential into other solid tumors. We operate as a C-corp, raising capital through equity financing to advance IND-enabling studies, with a platform licensing and M&A-driven exit strategy.